Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 May 2:2019:2912361.
doi: 10.1155/2019/2912361. eCollection 2019.

Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study

Shokouh Taghipour Zahir  1 , Zahra Heidarymeybodi  2 , Sogol AleSaeidi  1
Affiliations
Observational Study

Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study

Shokouh Taghipour Zahir et al. Int J Surg Oncol. .

Abstract

This study examines survival time in patients with small bowel tumors and determines its contributing factors. In this retrospective analytical study, the medical records of 106 patients with small bowel cancer (from 2006 to 2011) were investigated. The patients' data were extracted, including age, gender, clinical presentation, location of tumor, histological type, grade of tumor, site of metastasis, and type of treatment. The Kaplan-Meier test was used to estimate the overall survival time and the Log-rank test to compare the survival curves. The Cox regression was also used to evaluate the effect of the confounding variables on survival time. This study was conducted on 106 patients with a median age of 60 years (Min: 7, Max: 87). The tumor types included adenocarcinoma (n=78, 73.6%), MALToma (n=22, 20.8%), neuroendocrine tumors (n=4, 3.8%), and sarcoma (n=2. 1.8%). Grade 3 adenocarcinomas had a significantly lower survival time (HR: 1.48, 95% CI: 0.46-2.86; P=.001). Combined therapy (chemotherapy and surgery) vs. single-therapy (only surgery) had no significant effects on the survival of the patients with MALToma (5 vs. 3 months, 95% CI: 1.89-5.26; P=.06). There were no significant differences between the survival time in adenocarcinoma and MALToma (12 vs. 20 months, 95% CI: 6.24-24.76; P=.49). Tumor grade was the only independent prognostic factor that affected survival in adenocarcinoma. The patients diagnosed with MALToma in the study also had a poor prognosis, and the type of treatment had no significant effect on their survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves illustrating overall survival of patients with MALToma who received chemotherapy after surgery (n =7) compared with patients who just had surgery (n =5).
Figure 2
Figure 2
Kaplan-Meier curve illustrating overall survival of adenocarcinoma (n=78) compared with other types of tumors (n=22).
See this image and copyright information in PMC

References

    1. Martin R. G. Malignant tumors of the small intestine. Surgical Clinics of North America. 1986;66(4):779–785. doi: 10.1016/S0039-6109(16)43988-5. - DOI - PubMed
    1. Giuliani A., Caporale A., Teneriello F., Alessi G., Serpieri S., Sammartino P. Primary tumors of the small intestine. International Surgery. 1985;70(4):331–334. - PubMed
    1. Herszenyi L., Tulassay Z. Epidemiology of gastrointestinal and liver tumors. European Review for Medical and Pharmacological Sciences. 2010;14(4):249–258. - PubMed
    1. Iddan G., Meron G., Glukhovsky A., Swain P. Wireless capsule endoscopy. Nature. 2000;405(6785):417–418. - PubMed
    1. Schottenfeld D., Beebe-Dimmer J. L., Vigneau F. D. The Epidemiology and Pathogenesis of Neoplasia in the Small Intestine. Annals of Epidemiology. 2009;19(1):58–69. doi: 10.1016/j.annepidem.2008.10.004. - DOI - PMC - PubMed

Publication types

MeSH terms